STOCK TITAN

CEO.CA's Inside the Boardroom: This Breast Cancer Tech by Izotropic Targets 50% of Women Currently Underserved

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Izotropic Corporation (OTCQB: IZOZF) was featured in CEO.CA's "Inside the Boardroom" interview on October 21, 2025, where CEO Robert Thast discussed the company's breast cancer technology and strategy.

The interview positions the technology as targeting 50% of women currently underserved by existing screening or diagnostic options and invites investors to view the full conversation via CEO.CA and YouTube. The piece also promotes CEO.CA as an investor social network with broad engagement and weekly executive interviews.

Izotropic Corporation (OTCQB: IZOZF) è stata presentata nell'intervista "Inside the Boardroom" di CEO.CA il 21 ottobre 2025, dove l'amministratore delegato Robert Thast ha discusso della tecnologia e della strategia dell'azienda per il cancro al seno.

L'intervista presenta la tecnologia come rivolta al 50% delle donne attualmente poco servite dagli attuali sistemi di screening o diagnostici e invita gli investitori a guardare la conversazione completa su CEO.CA e YouTube. L'articolo promuove inoltre CEO.CA come una rete sociale per investitori con ampia partecipazione e interviste settimanali agli executive.

Izotropic Corporation (OTCQB: IZOZF) fue presentada en la entrevista de CEO.CA "Inside the Boardroom" el 21 de octubre de 2025, donde el CEO Robert Thast discutió la tecnología y la estrategia de la empresa para el cáncer de mama.

La entrevista posiciona la tecnología como dirigida al 50% de las mujeres actualmente desatendidas por las opciones de cribado o diagnóstico existentes y convoca a los inversionistas a ver la conversación completa a través de CEO.CA y YouTube. El artículo también promociona CEO.CA como una red social de inversionistas con amplia participación y entrevistas ejecutivas semanales.

Izotropic Corporation (OTCQB: IZOZF)는 CEO.CA의 "Inside the Boardroom" 인터뷰에 2025년 10월 21일에 등장했고, CEO Robert Thast가 회사의 유방암 기술과 전략에 대해 논의했습니다.

인터뷰는 이 기술을 현재 기존 선별 또는 진단 옵션에 의해 서비스를 받지 못하는 여성의 50%를 대상으로 한다고 제시하며 투자자들에게 CEO.CA와 YouTube를 통해 전체 대화를 볼 것을 권장합니다. 이 글은 또한 투자자 소셜 네트워크로서의 CEO.CA를 광범위한 참여와 주간 경영진 인터뷰와 함께 홍보합니다.

Izotropic Corporation (OTCQB: IZOZF) a été présentée dans l'interview "Inside the Boardroom" de CEO.CA le 21 octobre 2025, où le PDG Robert Thast a discuté de la technologie et de la stratégie de l'entreprise pour le cancer du sein.

L'interview présente la technologie comme visant 50 % des femmes actuellement mal desservies par les options de dépistage ou de diagnostic existantes et invite les investisseurs à visionner l'intégralité de la conversation via CEO.CA et YouTube. L'article fait également la promotion de CEO.CA en tant que réseau social pour investisseurs avec une large participation et des entretiens hebdomadaires avec les cadres.

Izotropic Corporation (OTCQB: IZOZF) wurde in CEO.CAs Interview "Inside the Boardroom" am 21. Oktober 2025 vorgestellt, in dem CEO Robert Thast die Technologie des Unternehmens gegen Brustkrebs und dessen Strategie erläuterte.

Das Interview positioniert die Technologie als Ausrichtung auf 50 % der Frauen, die derzeit von bestehenden Screening- oder Diagnostikoptionen nicht ausreichend erreicht werden und fordert Investoren auf, das volle Gespräch über CEO.CA und YouTube anzusehen. Der Beitrag bewirbt zudem CEO.CA als Investoren-Soziales Netzwerk mit breiter Beteiligung und wöchentlichen Führungskräfteinterviews.

Izotropic Corporation (OTCQB: IZOZF) تم عرضها في مقابلة CEO.CA "Inside the Boardroom" في 21 أكتوبر 2025، حيث ناقش الرئيس التنفيذي روبرت ثاست تكنولوجيا الشركة واستراتيجيتها لعلاج سرطان الثدي.

تموضع المقابلة التكنولوجيا كاستهداف 50% من النساء اللاتي لا يتم خدمتهم حالياً من قبل خيارات الفحص أو التشخيص القائمة وتدعو المستثمرين لمشاهدة الحوار الكامل عبر CEO.CA وYouTube. كما يروّج المقال لـ CEO.CA كشبكة اجتماعية للمستثمرين بمشاركة واسعة ومقابلات تنفيذية أسبوعية.

Izotropic Corporation (OTCQB: IZOZF) 在 CEO.CA 的「Inside the Boardroom」访谈中亮相,时间为 2025年10月21日,CEO Robert Thast 讨论了公司在乳腺癌领域的技术与策略。

该访谈将该技术定位为面向目前被现有筛查或诊断选项服务不足的 50% 女性,并邀请投资者通过 CEO.CA 和 YouTube 查看完整对话。该报道还将 CEO.CA 推广为投资者社交网络,强调广泛参与和每周的高管访谈。

Positive
  • None.
Negative
  • None.

Toronto, Ontario--(Newsfile Corp. - October 21, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.

Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.

Meet the Executive Shaping the Bio Tech Landscape

'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.

We caught up with Robert Thast, CEO of Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3). Follow what investors are saying and join our community: https://ceo.ca/izo

Izotropic Corporation
(CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)



Cannot view this video? Visit:
https://www.youtube.com/watch?v=-0qCmBojFJk

Tune into 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.

Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ceo.ca for further details and opportunities.

About CEO.CA

The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.

CEO.CA is a wholly owned subsidiary of EarthLabs, Inc.

For further information please contact:

CEO.CA
Email: hello@ceo.ca
Website: CEO.CA

Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271210

FAQ

What did Izotropic (OTCQB: IZOZF) announce in the October 21, 2025 CEO.CA interview?

CEO Robert Thast discussed Izotropic's breast cancer technology and said it targets 50% of women currently underserved by current options.

Where can investors watch the Izotropic (IZOZF) "Inside the Boardroom" interview from October 21, 2025?

The interview is available on CEO.CA and on YouTube at the link provided in the CEO.CA post.

Who is the CEO of Izotropic featured in the October 21, 2025 interview?

The interview features Robert Thast, identified as CEO of Izotropic Corporation.

Does the CEO.CA interview provide financial or clinical trial data for Izotropic (IZOZF)?

No; the published piece is an executive interview and does not include financial figures or clinical trial data.

How often does CEO.CA publish "Inside the Boardroom" interviews for companies like Izotropic (IZOZF)?

CEO.CA publishes the "Inside the Boardroom" interview series weekly, offering executive conversations and company updates.
Izotropic Canada

OTC:IZOZF

IZOZF Rankings

IZOZF Latest News

IZOZF Stock Data

14.43M
60.91M
8.62%
0.05%
Diagnostics & Research
Healthcare
Link
Canada
Surrey